UCLA
UCLA Previously Published Works

Title

Multi-Tissue Multi-Omics Nutrigenomics Indicates Context-Specific Effects of Docosahexaenoic Acid on Rat Brain

Permalink

https://escholarship.org/uc/item/25t5x3p2

Journal

Molecular Nutrition & Food Research, 64(23)

ISSN

1613-4125

Authors

Zhang, Guanglin
Meng, Qingying
Blencowe, Montgomery
et al.

Publication Date

2020-12-01

DOI

10.1002/mnfr.202000788

Peer reviewed

Multi-tissue Multi-omics Nutrigenomics Indicates Context-specific Effects of DHA on Rat Brain

Guanglin Zhang[1,4], **Qingying Meng**[1], **Montgomery Blencowe**[1,2], **Rahul Agrawal**[1,4,5], **Fernando Gomez-Pinilla**[1,4,5], **Xia Yang**[1,2,3,*]

[1]Department of Integrative Biology and Physiology, University of California, Los Angeles, 610 Charles E. Young Drive East, Los Angeles, CA 90095, USA

[2]Molecular, Cellular, and Integrative Physiology Interdepartmental Program, University of California, Los Angeles, 610 Charles E. Young Drive East, Los Angeles, CA 90095, USA

[3]Institute for Quantitative and Computational Biosciences, University of California, Los Angeles, 610 Charles E. Young Drive East, Los Angeles, CA 90095, USA

[4]Department of Neurosurgery, University of California, Los Angeles, Los Angeles, CA, 90095, USA

[5]Brain Injury Research Center, University of California, Los Angeles, Los Angeles, CA, 90095, USA

Abstract

Scope: We explored the influence of DHA on cardiometabolic and cognitive phenotypes, and multiomic alterations in the brain under two metabolic conditions to understand context-specific nutritional effects.

Methods and Results: Rats were randomly assigned to a DHA-rich or a control chow diet while drinking water or high fructose solution, followed by profiling of metabolic and cognitive phenotypes and the transcriptome and DNA methylome of the hypothalamus and hippocampus. DHA reduced serum triglyceride and improved insulin resistance and memory exclusively in the fructose-consuming rats. In hippocampus, DHA affected genes related to synapse functions in the chow group but immune functions in the fructose group; in hypothalamus, DHA altered immune pathways in the chow group but metabolic pathways in the fructose group. Network modeling revealed context-specific regulators of DHA effects, including *Klf4* and *Dusp1* for chow condition and *Lum*, *Fn1*, and *Col1a1* for fructose condition in hippocampus, as well as *Cyr61*, *JunB*, *Ier2*, and *Pitx2* under chow condition and *Hcar1*, *Cdh1*, and *Osr1* under fructose condition in hypothalamus.

*****Correspondence:** Xia Yang, Ph.D., Department of Integrative Biology and Physiology, University of California Los Angeles, Los Angeles, CA 90095, Phone: 310-206-1812, xyang123@ucla.edu.

Conclusion: DHA exhibits differential influence on epigenetic loci, genes, pathways, and metabolic and cognitive phenotypes under different dietary contexts, supporting population stratification in DHA studies to achieve precision nutrition.

Keywords

docosahexaenoic acid; epigenome; hippocampus; hypothalamus; transcriptome

1. Introduction

Long-chain polyunsaturated fatty acids (PUFAs), particularly omega-3 (n-3) PUFAs, have been indicated to play important roles in various aspects of human health [1]. Among the abundant n-3 PUFAs,docosahexaenoic acid (DHA; 22:6 n-3),in particular, has been extensively investigated. n-3 PUFAs may be beneficial for a broad range of disorders affecting both peripheral metabolism and brain functions, including obesity, hypertension, type 2 diabetes (T2D), insulin resistance, coronary heart disease (CHD), cardiovascular disease (CVD), cognitive disorders, and traumatic brain injury [2–5]. Our previous research uncovered that rats fed with n-3 diet counteracted both metabolic and cognitive deficits induced by high fructose consumption [6].

Despite the numerous positive reports on the potential beneficial effects of n-3 PUFAs, controversies have also arisen. Multiple studies suggested that n-3 PUFAs have a favorable effect on plasma triglyceride levels but no effect on cholesterol, glycemic, insulin or insulin resistance in T2D or metabolic syndrome patients [7]. Similarly, lack of effects has also been reported for the cardiovascular benefits of n-3 PUFAs [8–12].

We hypothesize that the conflicting findings may be a result of context-specific effects of DHA, that is, the benefits of DHA only manifest under specific pathophysiological conditions. Here we aim to employ high-throughput genomic and systems biology approaches to thoroughly investigate the phenotypic, transcriptomic, and epigenetic changes induced by DHA, a commonly studied n-3 PUFA, under different dietary contexts. Our results support profound context-specific alterations in genes, pathways, and epigenetic sites in individual brain regions affected by DHA despite certain similarities between contexts, thereby offering molecular insights into the differential activities of DHA that are dependent upon the physiological states of the host. These findings offer insights into the controversies observed in epidemiological and experimental studies regarding the benefits or lack of benefits of n-3 PUFA and support the need for more thorough future studies of PUFAs stratified by the metabolic conditions of the study subjects.

2. Experimental Section

Animals

As shown in Figure 1A, two months old male Sprague-Dawley rats (Charles River Laboratories, Inc., MA, USA) were randomly assigned to four groups: Chow control diet (#5001, LabDiet, St. Louis, MO and drinking water, n = 8), Chow + DHA (Chow diet supplemented with omega-3 fatty acid diet rich in DHA, n = 8), Fructose (Chow diet and

15% fructose, n = 8), Fructose + DHA (Chow and DHA with free access to 15% fructose, n = 8). The rats were singly housed at room temperature (22–24°C) with 12h light/dark cycle. Metabolic phenotypes including body weight, serum levels of insulin, glucose, and triglycerides, and insulin resistance index (fasting glucose [mg/dl] × fasting insulin [ng/ml] / 16.31) were examined. Rats were trained in the Barnes maze device for 5 days before diet treatment, followed by memory retention test after 6 weeks of treatment. Then rats were sacrificed, and hypothalamus and hippocampus tissues were dissected out, flash frozen, and stored at −70°C for subsequent transcriptome and epigenomic studies.

Dosage information

Rats were fed n-3 PUFA rich in DHA (1.2% of DHA, Nordic Naturals, Inc., CA, USA) at final dose of 620 mg/kg body weight which falls within common dose ranges [13] used in animals. According to the conversion guidance [14], the corresponding human equivalent dose is 100 mg/kg, which is within the dose range used in human clinical trials [15].

RNA Sequencing (RNA-Seq) and Data Analysis

Total RNA was extracted from hypothalamus and hippocampus (n = 4 per dietary group per tissue; total 32 samples) using an All-Prep DNA/RNA Mini Kit (QIAGEN GmbH, Hilden, Germany). Sample size was based on previous RNA-Seq studies in which findings were validated using qPCR and gene perturbation experiments [6, 16, 17]. Quantity and quality of RNA were checked using Qubit 2.0 Fluorometer (Life Technologies, NY, USA) and Bioanalyzer 2100 (Agilent Technologies, CA, USA). Two hypothalamus samples from the fructose group and DHA group failed standard quality control and were removed from the analysis. RNA-Seq libraries were prepared according to the standard Illumina protocol. Sequencing was performed in 100bp paired-end mode on HiSeq 2000 (Illumina Inc, CA, USA). RNA-Seq analysis was performed using the Tuxedo package as described previously [6]. Genes and transcripts showing differential expression or alternative splicing at p < 0.01 in each brain region were defined as a gene "signature" for further integrative analyses. DEGs were assessed for enrichment of pathways using the KOBAS web server [18]. Pathways at FDR < 5% were considered significant. RNA-Seq data was deposited to Gene Expression Omnibus (GEO) under accession numbers GSE59918 (both brain regions from control and fructose) and GSE64815 (both brain regions from fructose with DHA diets), and GSE89176 (both brain regions from the DHA diet).

Bayesian network construction

Bayesian Networks (BNs) are directed acyclic graphs representing conditional dependencies of genes in regard to their parent nodes. Across all the network genes a joint probability distribution can be defined through network topology. We constructed brain BNs using several mouse and human datasets as our input [17] and the RIMBANET package [19]. Using the Monte Carlo Markov Chain simulation, 1000 BNs with different random seed genes selected from the top ~5000 most variable genes were reconstructed for each dataset, and we determined the model of best fit for each network. From the set of 1000 networks constructed, a consensus network was formed if edges appeared in more than 30% of the networks. To be able to determine causal direction between genes, we used genetic information as priors for the network.

DHA DEG Network construction using a Weighted key driver analysis (wKDA)

wKDA is a step within the Mergeomics pipeline [20], used to predict potential key regulators, which we term key drivers (KDs). The wKDA step overlays the DHA DEGs from our hypothalamic and hippocampal data onto the brain BNs described above, with the aim to identify key drivers, whose network neighbors are highly enriched for DHA DEGs as compared to random genes within the network. We use a chi-square like statistic for the wKDA: $\chi \quad \frac{O-E}{\sqrt{E-\kappa}}$, where O is the 'observed' and E is the 'expected' ratios of genes from DHA DEG sets in a hub subnetwork, and a stability parameter of $\kappa = 1$ is used to reduce artefacts from low expected counts for small gene sets. $E \quad \frac{N_k N_p}{N}$ is estimated using the hub degree N_k, DHA DEG gene set size N_p and the order of the full network N. Statistical significance of the DHA DEG hubs, henceforth KDs, is estimated by permuting the network gene labels 10000 times and estimating the p-value based on the null distribution. Benjamini-Hochberg adjustment was used to estimate FDR to control for multiple testing. Network genes reaching FDR < 5% were considered as potential KDs. The gene subnetworks of KDs were visualized using Cytoscape [21].

Reduced Representation Bisulfite Sequencing (RRBS) of DNA Methylome

RRBS libraries of DNA samples (n = 4 per treatment group per brain region; total 32 samples) were prepared as described previously [6]. One hypothalamus sample from the fructose+DHA group was removed due to low quality. Loci with methylation levels > 25% between groups and FDR < 5% were considered as differentially methylated loci (DMLs). DMLs adjacent genes (within 10kb) were assessed for enrichment of pathways using the KOBAS web server [18]. Pathways at FDR < 5% were considered significant. RRBS data was deposited to GEO under accession numbers GSE59893 (both brain regions from control and fructose), GSE64816 (both brain regions from fructose with DHA diets), and GSE89176 (both regions from the DHA diet).

3. Results

3.1. Effect of DHA supplementation on metabolic and behavioral phenotypes.

Under the chow diet condition, DHA supplementation did not significantly alter metabolic phenotypes including plasma triglycerides, glucose, insulin level and insulin resistance index (Figure 1B–E), or the memory phenotype measured by latency time in the Barnes maze test (Figure 1F), although there were non-significant trends toward decreased triglycerides and latency time. By contrast, when rats were fed a 15% high fructose diet to induce metabolic syndrome, DHA supplementation significantly improved insulin resistance index in addition to reducing triglycerides and latency time in memory retention [6] (Figure 1), indicating beneficial effects of DHA under a metabolically challenged condition. There was no significant alteration of body weight by DHA under either chow or fructose conditions (Figure 1G).

3.2. Transcriptomic alterations in rat hippocampus and hypothalamus induced by DHA supplementation to a chow diet.

Despite a lack of significant phenotypic changes after DHA supplementation on a chow diet background, through RNA-Seq, we identified 169 and 388 DEGs, 107 and 252 differentially expressed transcripts, and 58 and 85 genes showing alternative exon usage in hippocampus and hypothalamus, respectively (Table S1). Overall, 240 unique hippocampal genes and 523 hypothalamic genes (including genes, transcripts, and alternative splicing) were defined as DHA DEGs, with 59 genes shared by the two tissues (Figure S1A). The expression pattern changes between control and DHA groups are stronger in the hypothalamus (Figure 2B) than in the hippocampus (Figure 2A).

To understand the biological functions of the DEGs affected by DHA supplementation, we evaluated the enrichment of the DEGs for biological pathways. We found 74 and 58 significantly enriched pathways at FDR < 5% from the hippocampal and hypothalamic DEGs, respectively, with 21 pathways shared by both (Table S2). The shared pathways between tissues include ECM-receptor interaction, Focal adhesion, and signaling pathways for PI3K-Akt, integrin, Rap1, and Wnt. The pathways unique to hippocampus include those highly relevant to neurotransmitter synapse functions, cardiomyopathy, and lipid metabolism. The hypothalamus-specific pathways include numerous innate immunity pathways, Axon guidance and Hippo signaling pathway (Table S2, Figure S1A). These results support that DHA induces tissue-specific molecular alterations in diverse functional processes without significant phenotypic manifestation under a physiological condition.

3.3. Comparison of DHA DEGs on a chow diet background with those on a high fructose diet.

We compared the DHA DEGs identified above from the chow diet background, representing a physiological condition, with those identified from rats consuming 15% fructose solution, a state of metabolic syndrome [6]. Under fructose consumption condition, we also identified tissue-specific as well as shared DEGs and pathways between hypothalamus and hippocampus (Figure S1B). Hypothalamus-specific pathways are mostly related to metabolism and neurotransmission, whereas immune and signaling pathways are specific to hippocampus. Focal adhesion and various signaling pathways for Akt-PI3K and integrin are shared between brain regions.

As shown in Table 1, although there were significant overlaps in the DHA DEGs identified from both chow and fructose conditions, many DEGs were context specific – either unique to each condition or show opposite patterns of expression changes between conditions. In general, more unique genes were affected by DHA when animals were fed a high fructose diet than when fed a control diet: 467 (Figure 2C) vs. 155 (Figure 2A) in hippocampus; 803 (Figure 2D) vs. 445 (Figure 2B) in hypothalamus. The expression patterns of DEGs affected by DHA supplementation differed between the chow and fructose backgrounds. For example, many DHA DEGs identified on the fructose background showed little discernable alterations by DHA when on a chow background (Figure 2C, 2D).

DHA DEGs unique to the chow condition were enriched for pathways related to inflammation, neuronal functions, and metabolism of linoleic acid and ether lipid, and mTOR signaling in hippocampus (Figure 2A, Figure S2, Table S2) and immune pathways in hypothalamus (Figure 2B, Figure S2, Table S2). Under the fructose condition, unique DEGs affected by DHA were enriched for immune pathways, Hippo signaling, and thyroid hormone synthesis in hippocampus (Figure 2C, Figure S2, Table S2) and oxidative phosphorylation pathway in hypothalamus (Figure 2D, Figure S2, Table S2).

Among the common DEGs affected by DHA on both the chow and the fructose backgrounds, we observed two distinct patterns – context-independent (i.e., up or downregulated in both conditions) and context-dependent (i.e., up in one condition but down in the other). In both hippocampus and hypothalamus, the context-independent DHA DEGs are enriched for pathways including ECM-receptor interaction, PI3K-Akt signaling pathway, and Focal adhesion, indicating their essential role in the effects of DHA (Figure 2E, Figure S2). For the context-dependent DEGs affected by DHA, genes involved TGF-beta signaling pathway and Wnt signaling were enriched in hypothalamus (Figure 2F, Figure S2).

Together, these results suggest that DHA supplementation not only affects certain consistent pathways but exerts unique effects on gene expression programs depending on the dietary and physiological background.

3.4.   Identification of tissue-specific key drivers (KDs) and subnetworks of DHA DEGs.

To explore the potential regulatory genes that mediate the action of DHA on the downstream targets under chow diet or fructose diet, we used a data-driven network analysis to capture gene-gene regulatory relations. In hippocampus, we identified 37 and 122 KDs whose subnetworks were enriched for DEGs affected by DHA on the chow diet and the fructose diet, respectively, at an FDR < 5%; in hypothalamus 68 KDs and 132 KDs were identified under chow diet and fructose diet. These results suggest more extensive gene network changes in both brain regions induced by DHA under the fructose condition compared to the chow diet (Figure 3A,3B).

Notably, the top KDs showed overlaps between chow and fructose conditions (Figure 3): *Fmod, Bgn, Serping1, Aldh1a2,* and *Pcolce*, mostly ECM genes, were top KDs for DEGs in both brain regions; *Slc13a4, Islr,* and *Asgr1* were consistent network KDs in hippocampus (Figure 3A); *Slc6a20* and *Cyp1b1* were shared KDs in hypothalamus (Figure 3B). Although these are shared KDs between chow and fructose conditions that are predicted to mediate the DHA effects on downstream genes, the DEGs surrounding these KDs in the gene networks are not necessarily the same between the chow and fructose conditions (pink versus blue nodes in Figure 3), suggesting differential gene regulation by these KDs depending on the interactions between DHA and the metabolic context.

In addition to these shared top KDs, we also found context-specific KDs of DEGs affected by DHA, including nine for chow condition (e.g., *Klf4* and *Dusp1*) and 95 for fructose condition (e.g., *Lum, Fn1, Col1a1*) in hippocampus, as well as 25 under chow condition (e.g., *Dusp1, Cyr61, JunB, Ier2, Pitx2*) and 27 for fructose condition (e.g., *Hcar1, Cdh1, Osr1*) in hypothalamus.

Collectively, ECM genes are the dominant and consistent type of KDs for DHA effects on the brain transcriptome, although other context-specific KDs such as *Klf4* and *Dusp1* for chow condition and *Hcar1* and *Osr1* for fructose condition also exist to regulate context-specific gene subnetworks. Many of these KDs are related to neuronal structural integrity and neural development and activity.

3.5. Context-specific DHA effects on the DNA Methylome.

To explore the epigenetic mechanisms underlying the regulation of the transcriptome associated with DHA, we profiled the DNA methylome in both hippocampus and hypothalamus. We identified DMLs between DHA treated and untreated groups at FDR < 5%.

Comparison of the DHA-associated DMLs identified on the chow diet background with those from the fructose-fed conditions revealed both significant overlaps and DMLs unique to each condition (Table 1). Among the shared DMLs in both conditions, both context-independent (i.e., consistent changes by DHA regardless of chow or fructose background; upper panels) and context-dependent DMLs (i.e., opposite changes by DHA in chow vs. fructose conditions; lower panels) were identified (Figure 4E–F). Interestingly, when both DHA and fructose were consumed, the DNA methylation patterns of the context-dependent DMLs were normalized back to the patterns in the chow diet condition. Therefore, agreeing with the transcriptome level data, our DNA methylome data also support context-specific effects of DHA supplementation.

Functional annotation of the genes adjacent to the DMLs revealed a broad range of pathways from ECM, neuronal signaling, and metabolic pathways to immune and endocrine pathways. Some of these pathways overlapped with those revealed through the transcriptome analysis but unique pathways such as thyroid hormone synthesis was also identified (Figure 4A–D). Similar to the transcriptome data, we also found brain-region specific as well as shared DMLs and pathways between hypothalamus and hippocampus under chow (Figure S3A) or fructose (Figure S3B) conditions. Neurotransmission pathways are shared between tissues under both conditions.

3.6. Relationship between DMLs and DEGs.

To investigate the relationship between DNA methylation and gene expression, we mapped the DNA methylation loci to adjacent genes within 10kb distance. Only 14 (7%) and 35 (6%) DHA DEGs identified under the chow diet condition and the fructose condition, respectively, were within 10kb distance to the DMLs in hippocampus; 17 (3%) and 39 (4%) DHA DEGs in the hypothalamus under chow and fructose diet condition, respectively (Table 2). A subset of these genes were shown to be significantly correlated with DMLs (Figure 5). The methylation within *Taok3* is negatively associated with obesity in children [22]. *Nptx2*, a member of neuronal pentraxins, has be linked to hippocampal synaptic plasticity in developmental and adult mice [23]. These results suggest a limited direct correlation between DMLs and DEGs measured at the same time point.

Some interesting genes among DEGs with local DMLs (Table 2) are transcription factors *Zbtb16* in hypothalamus (chow condition) and *Zbtb7a* in hippocampus (fructose condition).

Crispld2, is required for the control of membrane trafficking during axon development of hippocampal neurons of rats [24]. *Fmod*, encoding the ECM proteoglycan fibromodulin, showed both epigenetic and transcriptomic changes and was a shared KD identified in the above transcriptome network analysis. Epigenetic modification of these regulatory genes upon DHA supplementation could trigger alterations in downstream target genes and networks.

4. Discussion

By comparing the multidimensional effects of DHA, encompassing cardiometabolic and cognitive phenotypes and multiomics alterations in two critical brain regions, between a chow diet background and a fructose consumption context, our study shows that dietary DHA supplementation improved select metabolic traits and brain function, and induced transcriptomic and epigenetic alterations in hypothalamic and hippocampal tissues in both context-independent and context-specific manners.

On the phenotypic level, DHA supplementation significantly reduced serum triglyceride on the fructose diet condition but had a non-significant decreasing trend in the chow condition. This is consistent with previous studies that suggested diets high in long chain omega-3 fatty acids, particularly EPA and DHA, reduces blood triglyceride levels [25]. Similarly, in terms of glycemic phenotypes, insulin resistance index, and memory retention, DHA did not affect these phenotypes significantly when examined on the chow diet background, but significantly improved these phenotypes in fructose-treated animals [6]. These context-specific effects observed in our rat model agree with the findings from a previous human meta-analysis study, which revealed that fish oil supplementation had no effects on insulin sensitivity when all individuals were considered but had beneficial effects on insulin sensitivity among individuals with at least one symptom of metabolic disorders in subgroup analysis [26]. These results indicate that the beneficial effects of DHA on metabolism and cognition need to be considered in the context of the pathophysiological states of individuals.

To explore the mechanisms underlying the context-dependent and independent phenotypic effects of DHA, we examined the transcriptome and epigenome of two brain regions relevant to cognition (hippocampus) and metabolic control (hypothalamus). Pathway analysis of the omics alterations revealed both shared and differential responses in the two brain regions in different metabolic contexts. In particular, genes and pathways related with tissue structure such as Focal adhesion and ECM-receptor interaction, and signal transduction pathways such as PI3K-Akt and Wnt signaling pathways were affected by DHA regardless of the dietary context, although the direction of changes in these genes/pathways are not necessarily the same between contexts. These pathways were also previously observed in PUFA fed rat hypothalamic region [27], and may represent the core functions of DHA in maintaining cell membrane function and cell signaling.

In the physiological context (chow diet condition), we found DHA modulates hippocampal pathways related with neuronal function such as serotonergic synapse, cholinergic synapse, GABAergic synapse, dopaminergic synapse, glutamatergic synapse, and lipid metabolism.

Alterations of similar pathways were also observed in the whole brain of rats fed with fish oil [28], in the hippocampus of mice on a fish oil diet [29], and in the hippocampus of stressed mice with n-3 PUFA supplementation [30]. DHA also affected the mTOR signaling pathway in hippocampus. In the hypothalamus, DHA-altered pathways were more related to the innate immunity, such as cytokine-cytokine receptors, NF-kappa B signaling pathway, Toll-like receptor signaling pathway.

In stark contrast, under the condition of fructose-induced metabolic syndrome, DHA altered different sets of pathways in these brain regions: overall downregulation of genes in immune pathways such as cytokine and TGF-beta signaling in hippocampus and upregulation of energy metabolism pathways such as oxidative phosphorylation in hypothalamus (Figure 6). In addition, we found that the thyroid hormone synthesis pathway was uniquely altered by DHA in the hippocampus under fructose consumption. Previously, transthyretin, a thyroid hormone transporter, was found to be enhanced by DHA-rich diet in old rat hippocampus [31], although fructose was not used in this study.

Between the two dietary conditions (chow vs. fructose) and between tissues, we also identified a consistent set of pathways affected by DHA, including ECM-receptor interaction, Focal adhesion, and PI3K-Akt signaling. These pathways act in or through plasma membrane, which was revealed to be the location of proteins encoded by the majority of genes affected by a fish oil enriched diet [32]. ECM, once known as a pure scaffold to support surrounding cells, is being recognized as an important regulator in neural development, such as proliferation, differentiation, morphogenesis, neuronal migration, formation of axonal process, the myelin sheath, and synapse [33]. Focal adhesion molecules regulate neuronal hyperactivity through the interaction between astrocytes and synapses [34]. Integrin-based focal adhesions connect the ECM to the actin cytoskeleton, which facilitates cell migration and sensing extracellular biochemical and mechanical status [35] (Figure 6). PI3k-Akt signaling is involved in insulin sensitivity through interaction with the insulin receptor and substrate IRS1/2 in the hypothalamus of rat [36].

Among the pathways discussed above, some have been previously connected with DHA mode of action, such as mTOR signaling uniquely found in chow condition, and TGF-beta, NF-kappa B, and cAMP signaling pathways specifically enriched under fructose condition in hippocampus (Figure 6A, Table S2). In hypothalamus, the previously implicated pathways included NF-kappa B, Toll-like receptor, and TNF signaling pathways under chow condition, as well as oxidative phosphorylation and cAMP signaling pathway under fructose condition (Figure 6B, Table S2).

In addition to confirming several previously known pathways, our analysis revealed novel pathways affected by DHA, such as the Hippo signaling pathway. Hippo signaling pathway is known to be closely associated with control of organ size and development. Recent studies implicate its role in neural functions, such as neuroinflammation and neuronal cell death [37]. In hypothalamus, Rap1 signaling pathway was also captured, which is involved in neuronal connectivity [38], hypothalamic inflammation and leptin sensitivity [39].

Agreeing with the transcriptome-level findings, the DNA methylation loci affected by DHA under the two dietary conditions were also drastically different. These major shifts in the tissue-specific epigenetic loci, genes, and pathways associated with DHA consumption under physiological (chow) and pathological (fructose) conditions highlight the interactions between DHA and the host metabolic states. It is likely that under physiological conditions, DHA balances hippocampal neuronal functions and hypothalamic immune homeostasis. However, in a metabolically challenged state such as high fructose consumption which induces neuroinflammation in hippocampus and perturbs metabolic functions in hypothalamus, DHA mitigates the immune dysfunction induced by fructose in the hippocampus but promotes metabolic homeostasis in the hypothalamus.

We note that direct overlap or correlation between transcriptome and DNA methylome signals is limited, which is consistent with findings from previous studies [16, 17, 40, 41]. One potential reason for the limited overlap is that DNA methylation may regulate non-local genes by affecting the three-dimensional organization of the chromatin. Such long-range regulation is missed and difficult to assess in our study due to the severe multiple testing penalty if we consider all methylation loci-gene pairs. Second, unlike other epigenetic mechanisms such as histone modifications that exhibit more dynamic and faster gene regulation, DNA methylation is more stable and long-lasting, and may influence long-term trajectories of gene expression, which means that DNA methylation changes at a given time point may not immediately translate into gene expression changes. Since we measured DNA methylation and gene expression at the same time point, the direct relationship between the two is weak. Dynamic profiling of both at multiple time points may help better address their relationship.

Our study also revealed potential network regulators of the genes and pathways affected by DHA within and between contexts. More network regulators were affected by DHA when metabolically challenged with fructose, implicating a much larger network level impact of DHA in this pathological condition. Regardless of conditions, there were many shared network regulators such as *Fmod* and *Bgn*, which were also previously identified as key intermediators of the fructose effects [6] and other conditions [16, 42], even though the expression levels of these genes are not necessarily high. As highly variable genes (i.e., genes with high degrees of changes between individuals) are preferentially selected in network modeling, the consistency of certain KDs across tissues and different conditions may indicate the particular sensitivity of these genes to respond to perturbations such as dietary alterations. *Fmod* also showed local DNA methylation changes under DHA treatment (Table 2). Both *Fmod* and *Bgn* encode ECM proteoglycans, which not only provide structural support but also play key regulatory roles in maintaining neuronal functions [33, 43] and metabolic homeostasis [6]. Among the KDs unique to the chow condition, *Dusp1* is a KD for both the hypothalamic and hippocampal DEGs altered by DHA. *Dusp1* has been implicated in neuroprotection [44, 45] and has been linked with diabetes related cognitive impairment [46]. *Klf4* is involved in neurite growth and regeneration in hippocampal and cortical neurons, and its dysregulation has been linked to various neurological disorders [47, 48].

The hippocampal KDs of DHA DEGs unique to the fructose condition include ECM-related genes such as *Lum* encoding Lumican, a protein implicated in collagen binding [49, 50], and the collagen gene *Col1a1*. Among KDs unique to the fructose condition in the hypothalamus is *Hcar1,* which is involved in the modulation of neuronal activity induced by lactate [51] in response to physical muscle exertion and resultant communication with the brain enhancing cerebral angiogenesis [52]. Another hypothalamic KD unique to the fructose condition is *Osr1*, a regulator in GABA-mediated depolarization process in brain development [53].

By employing multidimensional approaches to investigate DHA effects on different tissues under physiological condition and diseased condition, our comprehensive study reveals the context-specific activities of DHA and the underlying molecular mechanism in the form of pathways and regulatory networks. Some of the key regulators uncovered, such as *Fmod* an *Bgn*, have been experimentally validated in terms of their effects on the network genes, cognition and metabolism [20, 54]. However, it is of importance to point out some potential limitations of this study. We acknowledge that only fructose was selected as an unhealthy diet in the current study, yet other types of sugars or combinations with other nutrients need to be tested. Secondly, certain important metabolic phenotypes such as fat mass and food intake were not measured, which could have provided additional metabolic insights. Lastly, individual genes or loci from our high throughput omics studies may need further replication, although we note that previous studies have demonstrated the accuracy of high throughput technologies [55–58].

In summary, DHA exerts distinct influence on metabolic traits and cognition between physiological and pathological conditions. Further investigation revealed transcriptomic and methylome changes in response to DHA under two conditions, offering mechanistic insights into the context-dependent pathways, networks, and key regulators, which may contribute to the differential metabolic and cognitive responses displayed. Our findings offer molecular support of the need for context-specific investigation of PUFAs to facilitate precision nutrition.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Data Availability Statement:

The data that supports the findings of this study are available in the supplementary material of this article

Abbreviations:

| PUFAs	Long-chain polyunsaturated fatty acids
EPA	Eicosapentaenoic acid

T2D	Type 2 diabetes
CHD	Coronary heart disease
CVD	Cardiovascular disease
RNA-Seq	RNA Sequencing
FDR	False discovery rate
GEO	Gene Expression Omnibus
wKDA	weighted key driver analysis
RRBS	Reduced Representation Bisulfite Sequencing
DMLs	Differentially methylated loci

5. References

[1]. von Schacky C, Angerer P, Kothny W, Theisen K, Mudra H, ANN INTERN MED 1999, 130, 554. [PubMed: 10189324]

[2]. Buckley JD, Howe PR, NUTRIENTS 2010, 2, 1212. [PubMed: 22254005]

[3]. Colussi G, Catena C, Novello M, Bertin N, Sechi LA, Nutr Metab Cardiovasc Dis 2017, 27, 191. [PubMed: 27692558]

[4]. Desai A, Park T, Barnes J, Kevala K, Chen H, Kim HY, J Neuroinflammation 2016, 13, 253. [PubMed: 27663791]

[5]. Shahidi F, Ambigaipalan P, Annu Rev Food Sci Technol 2018, 9, 345. [PubMed: 29350557]

[6]. Meng Q, Ying Z, Noble E, Zhao Y, Agrawal R, Mikhail A, Zhuang Y, Tyagi E, Zhang Q, Lee JH, Morselli M, Orozco L, Guo W, Kilts TM, Zhu J, Zhang B, Pellegrini M, Xiao X, Young MF, Gomez-Pinilla F, Yang X, EBioMedicine 2016, 7, 157. [PubMed: 27322469]

[7]. MacLean CH, Mojica WA, Morton SC, Pencharz J, Hasenfeld Garland R, Tu W, Newberry SJ, Jungvig LK, Grossman J, Khanna P, Rhodes S, Shekelle P, Evid Rep Technol Assess (Summ) 2004, 1.

[8]. Schwab U, Lauritzen L, Tholstrup T, Haldorssoni T, Riserus U, Uusitupa M, Becker W, FOOD NUTR RES 2014, 58.

[9]. Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, Gibson H, Albert CM, Gordon D, Copeland T, D'Agostino D, Friedenberg G, Ridge C, Bubes V, Giovannucci EL, Willett WC, Buring JE, V. R. Group, N Engl J Med 2019, 380, 23. [PubMed: 30415637]

[10]. Siscovick DS, Barringer TA, Fretts AM, Wu JH, Lichtenstein AH, Costello RB, Kris-Etherton PM, Jacobson TA, Engler MB, Alger HM, Appel LJ, Mozaffarian D, L. American Heart Association Nutrition Committee of the Council on, H. Cardiometabolic, E. Council on, Prevention, Y. Council on Cardiovascular Disease in the, C. Council on, N. Stroke, C. Council on Clinical, CIRCULATION 2017, 135, e867. [PubMed: 28289069]

[11]. Abdelhamid AS, Martin N, Bridges C, Brainard JS, Wang X, Brown TJ, Hanson S, Jimoh OF, Ajabnoor SM, Deane KH, Song F, Hooper L, Cochrane Database Syst Rev 2018, 7, CD012345. [PubMed: 30019767]

[12]. Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, Deane KH, AlAbdulghafoor FK, Summerbell CD, Worthington HV, Song F, Hooper L, Cochrane Database Syst Rev 2018, 7, CD003177. [PubMed: 30019766]

[13]. Ghasemi Fard S, Wang F, Sinclair AJ, Elliott G, Turchini GM, Crit Rev Food Sci Nutr 2019, 59, 1684. [PubMed: 29494205]

[14]. Nair AB, Jacob S, J Basic Clin Pharm 2016, 7, 27. [PubMed: 27057123]

[15]. Kim W, McMurray DN, Chapkin RS, Prostaglandins Leukot Essent Fatty Acids 2010, 82, 155. [PubMed: 20188532]

[16]. Meng Q, Zhuang Y, Ying Z, Agrawal R, Yang X, Gomez-Pinilla F, EBioMedicine 2017, 16, 184. [PubMed: 28174132]

[17]. Shu L, Meng Q, Diamante G, Tsai B, Chen YW, Mikhail A, Luk H, Ritz B, Allard P, Yang X, ENDOCRINOLOGY 2019, 160, 409. [PubMed: 30566610]

[18]. Xie C, Mao X, Huang J, Ding Y, Wu J, Dong S, Kong L, Gao G, Li CY, Wei L, NUCLEIC ACIDS RES 2011, 39, W316. [PubMed: 21715386]

[19]. Zhu J, Zhang B, Smith EN, Drees B, Brem RB, Kruglyak L, Bumgarner RE, Schadt EE, NAT GENET 2008, 40, 854. [PubMed: 18552845]

[20]. Shu L, Zhao Y, Kurt Z, Byars SG, Tukiainen T, Kettunen J, Orozco LD, Pellegrini M, Lusis AJ, Ripatti S, Zhang B, Inouye M, Makinen VP, Yang X, BMC Genomics 2016, 17, 874. [PubMed: 27814671]

[21]. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T, GENOME RES 2003, 13, 2498. [PubMed: 14597658]

[22]. Huang RC, Garratt ES, Pan H, Wu Y, Davis EA, Barton SJ, Burdge GC, Godfrey KM, Holbrook JD, Lillycrop KA, EPIGENETICS-US 2015, 10, 995.

[23]. Pelkey KA, Barksdale E, Craig MT, Yuan X, Sukumaran M, Vargish GA, Mitchell RM, Wyeth MS, Petralia RS, Chittajallu R, Karlsson RM, Cameron HA, Murata Y, Colonnese MT, Worley PF, McBain CJ, NEURON 2016, 90, 661. [PubMed: 27151642]

[24]. Wang T, Liu Y, Xu XH, Deng CY, Wu KY, Zhu J, Fu XQ, He M, Luo ZG, DEV CELL 2011, 21, 431. [PubMed: 21856246]

[25]. Shearer GC, Savinova OV, Harris WS, Biochim Biophys Acta 2012, 1821, 843. [PubMed: 22041134]

[26]. Gao H, Geng T, Huang T, Zhao Q, LIPIDS HEALTH DIS 2017, 16, 131. [PubMed: 28673352]

[27]. Fernandes MF, Tache MC, Klingel SL, Leri F, Mutch DM, Prostaglandins Leukot Essent Fatty Acids 2018, 128, 67. [PubMed: 29413363]

[28]. Kitajka K, Puskas LG, Zvara A, Hackler L Jr., Barcelo-Coblijn G, Yeo YK, Farkas T, Proc Natl Acad Sci U S A 2002, 99, 2619. [PubMed: 11880617]

[29]. Berger A, Mutch DM, German JB, Roberts MA, LIPIDS HEALTH DIS 2002, 1, 2. [PubMed: 12617750]

[30]. Vancassel S, Leman S, Hanonick L, Denis S, Roger J, Nollet M, Bodard S, Kousignian I, Belzung C, Chalon S, J LIPID RES 2008, 49, 340. [PubMed: 17991757]

[31]. Puskas LG, Kitajka K, Nyakas C, Barcelo-Coblijn G, Farkas T, Proc Natl Acad Sci U S A 2003, 100, 1580. [PubMed: 12566565]

[32]. Hammamieh R, Chakraborty N, Gautam A, Miller SA, Muhie S, Meyerhoff J, Jett M, PLOS ONE 2014, 9, e90425. [PubMed: 24632812]

[33]. Barros CS, Franco SJ, Muller U, Cold Spring Harb Perspect Biol 2011, 3, a005108. [PubMed: 21123393]

[34]. Cho S, Muthukumar AK, Stork T, Coutinho-Budd JC, Freeman MR, Proc Natl Acad Sci U S A 2018, 115, 11316. [PubMed: 30327343]

[35]. Case LB, Waterman CM, NAT CELL BIOL 2015, 17, 955. [PubMed: 26121555]

[36]. Niswender KD, Morrison CD, Clegg DJ, Olson R, Baskin DG, Myers MG Jr., Seeley RJ, Schwartz MW, DIABETES 2003, 52, 227. [PubMed: 12540590]

[37]. Cheng J, Wang S, Dong Y, Yuan Z, FRONT IMMUNOL 2020, 11, 281. [PubMed: 32140159]

[38]. Lilja J, Ivaska J, J CELL SCI 2018, 131.

[39]. Kaneko K, Xu P, Cordonier EL, Chen SS, Ng A, Xu Y, Morozov A, Fukuda M, CELL REP 2016, 16, 3003. [PubMed: 27626668]

[40]. Ohashi K, Munetsuna E, Yamada H, Ando Y, Yamazaki M, Taromaru N, Nagura A, Ishikawa H, Suzuki K, Teradaira R, Hashimoto S, Biochem Biophys Res Commun 2015, 468, 185. [PubMed: 26519879]

[41]. Yamazaki M, Yamada H, Munetsuna E, Ishikawa H, Mizuno G, Mukuda T, Mouri A, Nabeshima T, Saito K, Suzuki K, Hashimoto S, Ohashi K, FASEB J 2018, 32, 2549. [PubMed: 29401579]

[42]. Zhang G, Byun HR, Ying Z, Blencowe M, Zhao Y, Hong J, Shu L, Chella Krishnan K, Gomez-Pinilla F, Yang X, Biochim Biophys Acta Mol Basis Dis 2020, 1866, 165569. [PubMed: 31669422]

[43]. Bonneh-Barkay D, Wiley CA, BRAIN PATHOL 2009, 19, 573. [PubMed: 18662234]

[44]. Flores B , von Bernhardi R, J ALZHEIMERS DIS 2012, 32, 417. [PubMed: 22810097]

[45]. Collins LM, O'Keeffe GW, Long-Smith CM, Wyatt SL, Sullivan AM, Toulouse A, Nolan YM, Neuromolecular Med 2013, 15, 435. [PubMed: 23584919]

[46]. Zhou J, Wang L, Ling S, Zhang X, EXP NEUROL 2007, 206, 201. [PubMed: 17601561]

[47]. Moore DL, Apara A, Goldberg JL, MOL CELL NEUROSCI 2011, 47, 233. [PubMed: 21635952]

[48]. Moon BS, Bai J, Cai M, Liu C, Shi J, Lu W, NAT COMMUN 2018, 9, 401. [PubMed: 29374155]

[49]. Svensson L, Narlid I, Oldberg A, FEBS LETT 2000, 470, 178. [PubMed: 10734230]

[50]. Hedbom E, Heinegard D, J BIOL CHEM 1993, 268, 27307. [PubMed: 8262971]

[51]. de Castro Abrantes H, Briquet M, Schmuziger C, Restivo L, Puyal J, Rosenberg N, Rocher AB, Offermanns S, Chatton JY, J NEUROSCI 2019, 39, 4422. [PubMed: 30926749]

[52]. Morland C, Andersson KA, Haugen OP, Hadzic A, Kleppa L, Gille A, Rinholm JE, Palibrk V, Diget EH, Kennedy LH, Stolen T, Hennestad E, Moldestad O, Cai Y, Puchades M, Offermanns S, Vervaeke K, Bjoras M, Wisloff U, Storm-Mathisen J, Bergersen LH, NAT COMMUN 2017, 8, 15557. [PubMed: 28534495]

[53]. Nugent BM, Valenzuela CV, Simons TJ, McCarthy MM, J NEUROSCI 2012, 32, 593. [PubMed: 22238094]

[54]. Chella Krishnan K, Kurt Z, Barrere-Cain R, Sabir S, Das A, Floyd R, Vergnes L, Zhao Y, Che N, Charugundla S, Qi H, Zhou Z, Meng Y, Pan C, Seldin MM, Norheim F, Hui S, Reue K, Lusis AJ, Yang X, CELL SYST 2018, 6, 103. [PubMed: 29361464]

[55]. Griffith M, Griffith OL, Mwenifumbo J, Goya R, Morrissy AS, Morin RD, Corbett R, Tang MJ, Hou YC, Pugh TJ, Robertson G, Chittaranjan S, Ally A, Asano JK, Chan SY, Li HI, McDonald H, Teague K, Zhao Y, Zeng T, Delaney A, Hirst M, Morin GB, Jones SJ, Tai IT, Marra MA, NAT METHODS 2010, 7, 843. [PubMed: 20835245]

[56]. Asmann YW, Klee EW, Thompson EA, Perez EA, Middha S, Oberg AL, Therneau TM, Smith DI, Poland GA, Wieben ED, Kocher JP, BMC GENOMICS 2009, 10, 531. [PubMed: 19917133]

[57]. Wu AR, Neff NF, Kalisky T, Dalerba P, Treutlein B, Rothenberg ME, Mburu FM, Mantalas GL, Sim S, Clarke MF, Quake SR, NAT METHODS 2014, 11, 41. [PubMed: 24141493]

[58]. Shi Y, He M, GENE 2014, 538, 313. [PubMed: 24440293]

Figure 1. Changes in metabolic and behavior phenotypes in response to DHA supplementation under physiological and fructose-induced metabolic syndrome contexts.

A) Schema of study design. B) Serum triglycerides. C) Blood glucose. D) Insulin. E) Insulin resistance index. F) Latency time in the memory retention probe in the Barnes Maze test. G) Body weight. * p < 0.05, ** p < 0.01 by ANOVA with Sidak test. Error bars in the plots are standard errors. N = 8/group. F + D: Fructose + DHA. Data of fructose and F+D from our previous study was used as comparison [6].

Figure 2. Heatmap of gene expression changes and enriched pathways under DHA supplementation with or without fructose treatment in hippocampus and hypothalamus.
Unique DEGs affected by DHA in hippocampus (A) and hypothalamus (B) in chow diet background. Unique DEGs affected by DHA in hippocampus (C) and hypothalamus (D) when consuming fructose. Common DEGs affected by DHA in both chow and fructose backgrounds in hippocampus (E) and hypothalamus (F) were further divided into context-independent DEGs (upper panels) and context-independent DEGs (lower panel). DEGs were determined by Tuxedo at P < 0.01. Top significantly enriched pathways (FDR < 5%) followed by fold enrichment and representative genes in brackets were shown. Blue to red

colors indicate low to high expression values. The outer frame in each plot denotes the group comparison from which DEGs were chosen. Numbers in brackets over heatmap represented the numbers of DEGs plotted. As alternative splicing has no expression values, the number was not included in the graph. F + D: Fructose + DHA. Data of fructose and F+D from our previous study was used as comparison [6].

Figure 3. Gene subnetwork and top network key drivers of DEGs under different conditions affected by DHA in hippocampus (A) and hypothalamus (B).

Figure 4. Heatmap of methylation changes and enriched pathways under DHA supplementation with or without fructose treatment in hippocampus and hypothalamus.
DHA DMLs (A, B) and fructose DMLs (C, D) were used to compare the methylation changes between different groups in two brain regions. DMLs shared by DHA vs Ctrl DMLs and fructose vs F + D (fructose + DHA) DMLs were separated into context-dependent/ independent categories. Blue to red colors indicate low to high expression values. The genes were mapped within 10 kb from DML. * indicted pathways or GO terms without reaching significant enrichment. Number in brackets represented number of genes.

Figure 5. Correlation between DNA methylation and gene expression under chow (A) and fructose (B) background.

The p-value was determined using Pearson correlation test and corrected using Benjamini–

Hochberg procedure. +: sense strand; -: anti-sense strand.

Figure 6. Schematic diagrams of mechanism of action of DHA.
The related significantly enriched pathways were highlighted with genes involved in hippocampus (A) and hypothalamus (B).

Table 1.

Overlap of DEGs and methylation loci affected by DHA on a chow diet vs fructose diet background. Enrichment p value was calculated using 2-sided Fisher's exact test.

Omics	Tissue	DHA vs. control	DHA+Fructose vs Fructose	Overlap	Fold enrichment	Enrichment P value
Transcriptome	hippocampus	214	544	70	10.5	p < 2.8e-52
Transcriptome	hypothalamus	523	920	165	6.0	p < 7.5e-85
DNA methylome	hippocampus	1777	1957	343	862.3	0
DNA methylome	hypothalamus	1191	1665	195	657.5	0

Table 2.

DEGs within a 10kb distance of DMLs affected by DHA on a chow diet vs fructose diet background.

Tissue	Ctrl vs. DHA	Fructose vs. Fructose + DHA
Hippocampus	*Coch, Dtnbp1, Fbln1, Gch1, Glra1, Gnat2, Hunk, Kcnh6, Mis18a, Pla2g5, Rbp1, Rhoj, Sardh, Sema3a*	*Aldh2, Cacna2d3, Camk1d, Ccl19, Cgnl1, Coch, Cplx3, Crispld2, Dio3, Eya2, F13a1, Fblim1, Fbln1, Gprc5a, Irs3, Jph2, LOC304131, Lrp1b, Ltbp1, Marveld1, Nptx2, Pdgfrb, Pdlim1, Pex11a, Prss23, Ptges, Ptrf, Rem1, RGD1305645, Rhoj, Slco2a1, Srpx, Vcl, Wisp2, Zbtb7a*
Hypothalamus	*Arl4d, Btbd9, Cdc25b, Chrnb3, Chst11, Coch, Elf2, Eltd1, Hmgcs2, Kcnip1, Lgals5, Lrguk, Pdgfrb, Pnpla1, Sel1l, Slc44a4, Zbtb16*	*Acaa1a, Acaa1b, Aldh1a1, Aspg, Bnc2, Chrnb3, Coch, Crispld2, Fbn1, Fmod, Fstl1, Gng2, Gng7, Kank4, Lhfpl2, LOC685612, Ltbp2, Marveld1, Mgat5, Mlc1, Myo10, Ncs1, Npy1r, Nsmf, Pex11a, Plagl1, Plekhf1, Plekhh2, RGD1562726, Rims4, Rpl11, Rps23, Slc9a2, Slco4a1, Smtn, St3gal6, Taok3, Tm4sf1, Tmsb10*